^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | P22077 (USP47 inhibitor, USP7 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1283 FLT3-ITD Degrades CEBPA Via the Ubiquitin-Proteosome Pathway
Published date:
11/03/2022
Excerpt:
FLT3-ITD AML cells were >2-fold more sensitive to P22077 than FLT3-wt AML cells (IC50 5.8 and 7.1 µM for MV411 and MOLM13 versus 13.65 and 21.7 µM for THP1 and K562 cells).
DOI:
https://doi.org/10.1182/blood-2022-166612
